Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study ; volume:26 ; number:4 ; year:2019 ; pages:260-267
Portuguese journal of gastroenterology ; 26, Heft 4 (2019), 260-267

Creator
Campos, Marta
Candelária, Isabel
Papanikolaou, Nickolas
Simão, Adélia
Ferreira, Carlos
Manikis, Georgios C.
Caseiro-Alves, Filipe

DOI
10.1159/000493351
URN
urn:nbn:de:101:1-2019071100202097469874
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:36 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Campos, Marta
  • Candelária, Isabel
  • Papanikolaou, Nickolas
  • Simão, Adélia
  • Ferreira, Carlos
  • Manikis, Georgios C.
  • Caseiro-Alves, Filipe

Other Objects (12)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib

Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib

Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker

Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker

Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib

Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib

Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study

Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study

Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib

Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

Biomarker in Hepatocellular Carcinoma

Biomarker in Hepatocellular Carcinoma

KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma

KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma

Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1

Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1

Related objects